Bicara Therapeutics Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 |
|---|---|---|---|
| Operating income | -$155.6M | -$82.4M | -$39.9M |
| Operating expenses | $155.6M | $82.4M | $39.9M |
| Cash from operations | -$106.8M | -$74.8M | -$45.6M |
| Capital expenditure | $280,000 | $71,000 | $586,000 |
| Free cash flow | -$107.1M | -$74.8M | -$46.2M |
| Impairments | $0 | $0 | $0 |
| Total assets | $431.0M | $510.0M | $234.0M |
| Total liabilities | $29.5M | $18.1M | $15.5M |
Shares outstanding 65.7M · Free float 74.7%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.